@article{142c052ab6ea416c9c846cec4809362e,
title = "Talking points for physicians, patients and caregivers considering Aduhelm{\textregistered} infusion and the accelerated pathway for its approval by the FDA",
keywords = "Aduhelm{\textregistered} (aducanumab), Amyloid beta, Donanemab, Gantenerumab, Lecanemab",
author = "Sam Gandy and Knopman, {David S.} and Mary Sano",
note = "Funding Information: Dr. Gandy serves as a consultant for Ritrova Therapeutics and as a founder of Recuerdo Pharmaceuticals (inactive). He has served as a consultant in the past for Diagenic, and he has received research support in the past from Warner-Lambert, Pfizer, Baxter, and Avid. He receives research support from the NIH. ",
year = "2021",
month = dec,
doi = "10.1186/s13024-021-00490-z",
language = "English",
volume = "16",
journal = "Molecular Neurodegeneration",
issn = "1750-1326",
publisher = "BioMed Central Ltd.",
number = "1",
}